A registration-quality trial of Firdapse for MuSK antibody positive Myasthenia Gravis.
Phase of Trial: Phase III
Latest Information Update: 31 Aug 2016
At a glance
- Drugs Amifampridine (Primary)
- Indications Myasthenia gravis
- Focus Registrational; Therapeutic Use
- 31 Aug 2016 New trial record
- 09 Aug 2016 According to Catalyst Pharmaceuticals media release, based on the positive data from another study (see profile 267531) company plans to initiate this trial. Special Protocol Assessment request has been submitted to the FDA.